of hypertension is as important as control of hyperglycemia for inducing remission/regression in patients with diabetic nephropathy. [5] [6] [7] Home blood pressure (HBP) measurements have several favorable properties. 8 HBP can be used to predict cardiovascular disease, cerebrovascular disease, and end-stage renal disease better than the clinic blood pressure (CBP) [9] [10] [11] [12] [13] and HBP measurements may be employed to evaluate daily variability in blood pressure (BP). The HBP measurements exhibit greater reproducibility than CBP measurements by taking the averages of several measured values. Moreover, HBP measurements may reveal masked and white coat hypertension.
The recommended target HBP is <125/75 mm Hg for hypertensive patients with diabetes mellitus (DM) according to the Ohasama study 14 and HOMED-BP study 15 in the guidelines of the Japanese Society of Hypertension. 16 However, there is currently insufficient information regarding the optimal HBP. The target HBP is not described in the guidelines of the Eighth Joint National Committee (JHC8) 17 and the American Diabetes Association (ADA). 18 There is not always a strong and significant correlation between CBP and HBP in treated hypertensive patients. 12, 14 Therefore, further evidence regarding HBP-based studies is required to establish the optimal HBP. The Home Blood Pressure for Diabetic Nephropathy (HBP-DN) study is a 3-year prospective cohort study designed to determine the optimal HBP to induce the remission/regression of diabetic nephropathy in patients with type 2 DM having microalbuminuria.
METHODS
The HBP-DN study is a multicenter study performed as part of the National Hospital Organization Multi-Center Clinical Research for Evidence-Based Medicine program. The subjects of this study were recruited from 29 hospitals belonging to the Japan National Hospital Organization. This study has 2 successive phases. The first phase consisted of a period of evaluation with 2 separate visits (visits 1 and 2) by subjects at which the urinary albumin-creatinine ratio (ACR) was measured using morning urine samples. The inclusion criteria were as follows: (i) type 2 DM, (ii) ACR between 30 and 300 mg/g creatinine (g Cr) obtained twice in succession, (iii) 20 to 75 years of age, and (iv) HbA1c level on visit 1 of <9.4% based on the National Glycohemoglobin Standardization Program. The exclusion criteria comprised: (i) pregnancy, (ii) inability to use the automatic cuff-oscillometric device, (iii) malignant tumors, (iv) patients in whom it was unwise to lower the BP too much (i.e., patients with orthostatic hypotension and/or a history of cerebral infarction within 6 months prior to obtaining consent), (v) nondiabetic nephropathy, (vi) congestive heart failure, and (vii) urinary tract infection or neurogenic bladder. The second phase included a 3-year follow-up of the patients (visits 3 through 6). During the follow-up periods, each subject underwent measurement of biochemical parameters under fasting conditions every 12 months. ACR was measured twice a year and the geometric mean ACR was calculated annually. Measurement procedures for urine albumin concentration are provided in the online Supplementary Table 1. ACR was classified as indicating normoalbuminuria for ACR of <30 mg/g Cr, microalbuminuria for ACR of ≥30 and <300 mg/g Cr, and overt proteinuria for ACR of ≥300 mg/g Cr. HBP records were collected twice a year. HBP was measured once in the morning and once in the evening using an automatic cuff-oscillometric device (Omron HEM-7471C, Kyoto, Japan). The patients were explained the procedure of HBP measurements as follows: HBP should be measured after rest in the seated position for 5 minutes. The morning measurement should be made at the time of getting up, after micturition, before drug ingestion, and before breakfast. The evening measurement should be made just before going to bed. 19 The patients were asked to record their BP readings for 7 days and to submit the report to their physician on visit 3 and twice a year thereafter. Therefore, one set of HBP records included the morning HBP and evening HBP for 7 days. Measurements of morning HBP and evening HBP were averaged every year. All measurements of morning HBP and evening HBP were also averaged every year and defined as all HBP. The SD of all measurements of HBP at baseline was also calculated. When the submitted HBP measurements were less than 70% of the expected HBP measurements, HBP for the year was treated as a deficit. CBP was measured with the subjects in the sitting position using the same automatic cuff-oscillometric device presented to participants.
The study was observational, and there were no specific recommendations with regard to the management of hypertension, including the type of drugs selected or the BP goal. The estimated glomerular filtration rate was calculated according to the Modified Diet for Renal Disease study equation modified for Japanese patients with chronic kidney disease as follows: estimated glomerular filtration rate (ml/min/1.73 m 2 ) = 194 × Cr −1.094 × Age −0.287 (×0.739, if female). 20 The geometric mean ACR obtained on visits 1 and 2 was used as the baseline ACR. HBP, CBP and laboratory values, except for ACR obtained on the day of visit 3 were used as baseline data. The average values of modifiable factors such as HbA1c, BP, and lipid values during the followup period were also calculated.
The decline in BP was defined as the "BP at baseline" minus the "mean BP during follow-up period". Mean all home systolic blood pressure (AHSBP) during the followup period was classified into the following categories: AHSBP <120 mm Hg, AHSBP between ≥120 and <125 mm Hg, AHSBP between ≥125 and <130 mm Hg, and AHSBP ≥130 mm Hg. Mean all home diastolic blood pressure (AHDBP) during the follow-up period was classified into the following categories: AHDBP <65 mm Hg, AHDBP between ≥65 and <70 mm Hg, AHDBP between ≥70 and <75 mm Hg, and AHDBP ≥75 mm Hg. ACR at baseline was also classified into the following categories: ACR between ≤30 and <50 mg/g Cr, ACR between ≥50 and <150 mg/g Cr, and ACR between ≥150 and <300 mg/g Cr.
Remission of microalbuminuria was defined as a shift from microalbuminuria to normoalbuminuria. Regression of microalbuminuria was defined as a 50% reduction in ACR from the baseline. 5 The Ethics Committee of Japan National Hospital Organization approved the study protocol and informed consent procedures. All patients gave their written informed consent. The protocol was submitted to the UMIN-Clinical Trial Registration on 1 September 2007, and its unique trial number is UMIN000000804.
RESULTS
The flow of the participants and reasons for exclusion from the analysis are shown in Figure 1 . There were 311 patients recruited from April 2008 to June 2009. Among these patients, 268 fulfilled the criteria. Thirty-three patients dropped out of the study within 1 year and excluded from analysis. The remaining 235 patients were included. The changes in ACR and modifiable factors are shown in Table 1 . The time courses of ACR and ASHBP in patients with and without remission/regression are shown in the online Supplementary Figures 1 and 2 .
The 3-year cumulative incidences of remission and regression were 32.3% and 44.7%, respectively. The numbers of the patients who were induced remission/regression are shown in the online Supplementary Table 3 . Doubling of the serum creatinine level occurred in one patient. No cases of end-stage renal disease were noted and all cause of death occurred in 6 patients. Cardiovascular events occurred in 5 patients, one of which was fatal and cerebrovascular events occurred in 7 patients, one of which was fatal.
Comparison of various factors between the groups with and without events
The clinical characteristics of the study groups stratified by the presence of remission and regression are shown in Table 2 . The baseline values of ACR were lower in the patients in the remission group than in patients in the no remission group. There were no differences in the means of HBP and CBP during the follow-up period between the 2 groups. In contrast, HBP declined more in the remission group than they did in the no remission group.
Mean HSBP during the follow-up period was lower in the regression group than in the no regression group. Declines in HBP and CBP during the follow-up period were similar between the 2 groups.
The results of the multivariate analysis using the Cox proportional hazards regression models are shown in Table 3 . ACR at baseline and the decrease in AHSBP independently affected the induction of remission. No factors influenced the induction of regression independently.
Analysis of the patients with AHSBP below 140 mm Hg at baseline
The decrease in AHSBP during the follow-up period affected the induction of remission. There was a strong positive relationship between AHSBP at baseline and the decline in AHSBP during the follow-up period (r = 0.656, P ≤ 0.00001). These results suggest that the patients with high BP at baseline demonstrated a greater possibility of remission induction following a decline in AHSBP. These patients should be eliminated from the analysis to exclude the effect of change in BP. The X intercept of the regression line for the decline in AHSBP during the follow-up period over AHSBP at baseline is 129.7 mm Hg (Supplementary Figure 3) . It indicates that the patients with AHSBP at baseline over 129.7 mm Hg should be eliminated from the analysis to exclude the effect of the decline in AHSBP. On the other hand, the optimal SBP recommended for the patients with diabetes and chronic kidney disease is below 140 mm Hg in the guidelines of the JHC8 and the ADA. Therefore, the patients with AHSBP at baseline up to 140 mm Hg should be included in the analysis to determine the optimal AHSBP. Therefore, a separate analysis was performed in the patients with AHSBP at baseline below 140 mm Hg (n = 153). As shown in Table 2 , the means of AHSBP during the followup period in the remission/regression groups were lower than those observed in the no remission/regression groups. The results of the multivariate analysis are shown in Table 3 . Baseline ACR, AHSBP, and CDBP during the follow-up period independently affected the induction of remission. Baseline ACR and AHSBP during the follow-up period independently affected the induction of regression. The multivariate analyses including both of MHSBP and EHSBP as independent variables were also performed. Results are provided in the online Supplementary Table 4 . EHSBP during the follow-up period independently affected the induction of remission. MHSBP during the follow-up period independently affected the induction of regression.
As shown in Table 4 , the hazard ratio for inducing remission was significantly lower in patients with mean AHSBP during the follow-up period above 130 mm Hg than it was in those with mean AHSBP below 120 mm Hg. The hazard ratio for inducing regression was also significantly lower in patients with mean AHSBP during the follow-up period above 130 mm Hg. On the other hand, remission was observed most frequently in the group of 70 ≤AHDBP <75. Regression was observed most frequently in the group of 65 ≤AHDBP <70. However, there were no significant differences in the hazard ratio for inducing remission/regression between AHDBP categories.
DISCUSSION
The incidence of both remission and regression in the current study was equivalent to that previously reported. 5, 6 The importance of albuminuria as a surrogate end point in clinical trials of renal disease is thought to be limited. 21, 22 First, it has been demonstrated that albuminuria does not always precede a decline in the glomerular filtration rate. 23, 24 Second, reduction in albuminuria is not always associated with subsequent renoprotection in intervention studies. [25] [26] [27] Third, reduction of albuminuria is not hard endpoint. As the result, not all the remission/regression cases kept remission/regression status in our study (Supplementary Figures  4 and 5) . However, it has been reported that a large change in albuminuria can predict renal outcome. 28 It has also been reported that a greater than 2-fold decrease in albuminuria is associated with better renal or cardiovascular outcomes. 29, 30 In this study, we defined 2 endpoints, remission, and regression of microalbuminuria. The changes in ACR defined in these endpoints are large enough to predict the renal outcomes. Fourth, there is the considerable intraindividual variation in albuminuria. The ACR is affected by Abbreviations: ACR, urinary albumin-creatinine ratio; AHDBP, all home diastolic blood pressure; AHSBP, all home systolic blood pressure; CDBP, clinic diastolic blood pressure; CSBP, clinic systolic blood pressure; EHDBP, evening home diastolic blood pressure; EHSBP, evening home systolic blood pressure; MHDBP, morning home diastolic blood pressure; MHSBP, morning home systolic blood pressure; ns, not significant; RAS, renin-angiotensin system; P, P value.
a Paired Student's t-test: vs. baseline. b χ square test vs. baseline. Table 2 . Clinical characteristics of the study groups stratified by the presence of remission and regression Abbreviations: ACR, urinary albumin-creatinine ratio; AHDBP, all home diastolic blood pressure; AHSBP, all home systolic blood pressure; CDBP, clinic diastolic blood pressure; Cr, creatinine; CSBP, clinic systolic blood pressure; eGFR, estimated glomerular filtration rate; EHDBP, evening home diastolic blood pressure; EHSBP, evening home systolic blood pressure; MHDBP, morning home diastolic blood pressure; MHSBP, morning home systolic blood pressure; ns, not significant; p, p value; RASi, renin-angiotensin system inhibitor; U-IV-coll, urinary type IV collage. Data are expressed as mean ± SD or percentage. a χ square test. the intraglomerular pressure and may be increased by high BP and exercise. In our study, we measured the ACR twice using a first morning urine sample 31 to minimize variation. Therefore, our results provide important information regarding the optimal HBP for improving renal outcomes of patients with type 2 DM having microalbuminuria. In our study, after analysis of all cases, the degree of AHSBP decline rather than mean AHSBP during the follow-up period influenced the induction of remission/ regression during the follow-up period. A decrease in systolic BP may reduce ACR via a hemodynamic mechanism. Moreover, we observed greater declines in AHSBP in the subjects with higher baseline AHSBP. Therefore, patients with inadequately controlled BP at baseline should be removed from the analysis to exclude the possibility that the ACR reduction was induced by hemodynamic changes. For this purpose, we performed separate analyses of the patients with AHSBP below 140 mm Hg at baseline, which showed that the degree of AHSBP decline did not influence the induction of remission or regression. However, mean AHSBP during the follow-up period independently affected the induction of both remission and regression (Table 3) .
We previously reported that the variability of AHSBP was significantly elevated in patients with microalbuminuria exhibiting a low estimated glomerular filtration rate. 32 However, we Abbreviations: ACR, urinary albumin-creatinine ratio; AHDBP, all home diastolic blood pressure; AHSBP, all home systolic blood pressure; CDBP, clinic diastolic blood pressure; CSBP, clinic systolic blood pressure; Cr, creatinine; eGFR, estimated glomerular filtration rate; ns, not significant; RASi, renin-angiotensin system inhibitor; U-IV-coll, urinary type IV collage.
did not observe any correlations between the SD of AHSBP at baseline and the induction of remission/regression (Table 2) .
Studies have established that HBP can be used to predict the incidence of cardiovascular disease events more accurately than CBP. [9] [10] [11] [12] In the present study, we demonstrated that AHSBP also affected the induction of remission/regression of microalbuminuria more than CSBP for the first time. It should be elucidated which is more important for the induction of remission/regression, MHSBP, or EHSBP. However, as shown in the online Supplementary Table 4 , it could not be concluded which is more important. In this study, we showed that lower AHDBP has no benefit for inducing remission/regression. In patients with diabetic nephropathy, the DBP may decrease owing to reduced compliance of large elastic arteries due to atherosclerosis. This suggests that a lower DBP does not lead to better renal outcomes. Finally, we sought to determine the optimal HSBP for inducing remission/regression and we also sought to examine whether there are J-shaped correlations between HBP and remission/regression or not. For these purposes, we divided mean AHSBP and AHDBP during the follow-up period into 4 categories. We found that the incidence of both remission/regression was lowest in the AHSBP <120 mm Hg group, but the rate of remission/regression in the AHSBP ≥130 mm Hg group was significantly lower than that in the AHSBP <120 mm Hg group. It has been reported that lower BP is associated with an increased incidence of nephropathy remission 7 and reduced risk of progression of diabetic nephropathy. 33 However, other studies report that intensive BP control increases the risk of adverse events. 34, 35 In addition, the incidence of stroke increased in patients with chronic kidney disease of stages 3 and 4 as the SBP decreases to below 120 mm Hg. 36 In our study, there were only a few patients with new-onset cardiovascular disease or cerebrovascular disease. Therefore, we could not evaluate the adverse effects induced by an excessive decrease in BP.
There are some limitations in our study. First, it is an observational study and not a randomized controlled trial. Second, the endpoints of this study are remission/regression of microalbuminuria and not hard endpoints. Third, procedures of measuring urine albumin concentration was not same in all hospitals. It has been reported that there is disagreement among routine measurement procedures of urine albumin. 37 Finally, the observation period was not long enough to evaluate the effects of HBP on the hard renal outcomes. Therefore, it is necessary to establish these limitations of our study to determine the optimal HBP for patients with type 2 DM having microalbuminuria.
In conclusion, we demonstrated the importance of measuring HBP for the induction of remission/regression of microalbuminuria. Optimal AHSBP to induce remission/regression of microalbuminuria in patients with type 2 DM might be below 130 mm Hg. However, as the data concerning subsequent clinical impact and outcome of the patients who achieved remission/regression of microalbuminuria are not provided in this study, further study is required to determine the optimal HBP. The HSBP categories, ACR categories, age, and gender were included as independent variables. Abbreviations: ACR, urinary albumin-creatinine ratio; AHDBP, all home systolic blood pressure; AHSBP, all home systolic blood pressure; CIs, confidence intervals; Cr, creatinine; HRs, hazard ratios.
